Quantcast
Top Stories
Consumer Discretionary
Healthcare
Editors' Picks
Merck (MRK) To Set Strong Foothold In Cancer Immunotherapy Market With Keytruda
Merck (MRK) To Set Strong Foothold In Cancer Immunotherapy Market With Keytruda

Merck’s Keytruda is considered the top PD-1 inhibitor in the market right now. Keytruda was successful in raking in a hefty $83 million in sales in 1QFY15

Forgot Password

Enjoy all premium content at BidnessEtc for free now!

Enjoy all premium content at BidnessEtc for free now!